-0.13 | -1.71%
| Price and Volume | |
|---|---|
| Recent Price | 7.60 |
| 52 Week High | 8.05 |
| 52 Week Low | 5.35 |
| Avg. Daily Vol. (Mil) | 0.14 |
| Beta (3 year) | 1.30 |
| Share Related Items | |
| Mkt Cap (Mil) | 372.94 |
| Shares Out (Mil) | 49.07 |
| Float (Mil) | 32.39 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 17.00 |
| Current Ratio | 21.50 |
| LT Debt/ Equity | 0.00 |
| Total Debt / Equity | n.a. |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 8.81 |
| Price/Book | 0.00 |
| Price/Cash Flow | -12.20 |
| Per Share Data | |
| Earnings | -0.65 |
| Sales | 0.86 |
| Book Value | 0.00 |
| Cash Flow | -0.62 |
| Business Summary | |
|---|---|
| QLT Inc. is a global biotechnology Company dedicated to the discovery, development and commercialization of innovative therapies. | |
| General Information | |
| 887 Great Northern Way
Suite-101 Vancouver, BC V5T 4T5 |
|
| www.qltinc.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 188 | |
| CEO: Mr. Robert L Butchofsky | |
| Short Interest | |
| Current Month (Mil) | 0.57 |
| Previous Month (Mil) | 0.60 |
| Short Interest Ratio (Days) | 4.10 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -9.60 |
| Return on Investments | -10.00 |
| Profitability | |
| Gross Margin | 75.30 |
| EBIT Margin | -72.50 |
| Profit Margin | -76.00 |
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note |
|
|---|---|---|---|---|
| 12,430.15 | 1,316.17 | 2,834.33 | 16.34 |
Oil *
103.43
|
|
DOWN
150.54 |
DOWN
16.25 |
DOWN
36.66 |
DOWN
0.97 |
10 Yr
1.63%
SPDR Gold
150.33
|
|
-1.20%
|
-1.22%
|
-1.28%
|
-5.60%
|
Data delayed 20 minutes |
Connect with TheStreet